The FDA’s New Herb Guidelines Are Missing the Point: He

The FDA’s updated guidance on botanical ingredients and herbal supplements has sparked significant debate among herbalists, integrative medicine practitioners, and wellness advocates. The core issue is straightforward: the agency’s framework prioritizes pharmaceutical-style safety thresholds and isolated compound analysis over the holistic, whole-plant traditions that have guided herbal medicine for centuries. While consumer protection matters deeply, the current regulatory approach risks stifling access to beneficial herbs while doing little to address the actual sources of harm in the supplement industry. This guide breaks down what the FDA’s guidelines get wrong, what they get right, and what a genuinely useful framework would look like.

What the FDA’s Current Herb Guidelines Actually Say

The FDA regulates herbal products primarily under the Dietary Supplement Health and Education Act (DSHEA) of 1994, which created a separate regulatory category for dietary supplements including herbs. Under this framework, manufacturers are responsible for ensuring their products are safe before marketing them. The FDA does not approve supplements before they reach shelves.

In recent years, the FDA has issued draft guidance documents focusing on new dietary ingredients (NDIs), which require manufacturers to notify the agency when introducing a botanical that was not marketed before October 1994. The agency has also increased scrutiny on specific herbs flagged for potential liver toxicity, drug interactions, or adulteration concerns.

The problem is not that these concerns are invented. Adulteration is real, and some herbs do carry genuine risks for certain populations. The problem is the methodology the FDA uses to evaluate those risks, which often borrows from pharmaceutical toxicology models that were never designed for whole-plant preparations used in traditional contexts.

The Pharmaceutical Lens Problem

When the FDA evaluates an herb for safety, it frequently focuses on isolating and measuring specific compounds, then applying risk thresholds derived from single-molecule drug studies. This approach made sense when the agency was reviewing synthetic pharmaceuticals. It creates serious distortions when applied to complex botanical matrices.

Consider how this plays out with something like kava (Piper methysticum), a traditional Pacific Island plant used for relaxation and ceremonial purposes. Regulatory agencies in Europe and North America largely restricted kava in the early 2000s based on reports of liver toxicity. Subsequent research suggested that many of those cases involved products made from non-traditional plant parts, used alongside alcohol, or were adulterated entirely. Traditional aqueous preparations used in Pacific Island communities showed a dramatically different safety profile. The pharmaceutical lens missed that context entirely.

The same issue arises with herbs like comfrey, pyrrolizidine alkaloid-containing plants, and even valerian. Regulatory documents often treat a chemical compound found in an herb as equivalent to the whole herb used at traditional doses in traditional preparations. This is not how herbalism works, and it is not how the evidence actually reads when contextualized properly.

What the Guidelines Actually Get Right

Fairness demands acknowledging what the FDA’s approach does address appropriately. The supplement industry is not without serious problems, and some of the agency’s interventions have been genuinely protective.

Adulteration is a documented crisis. Studies and testing programs run by organizations like ConsumerLab have repeatedly found that a meaningful portion of herbal supplements on the market do not contain what their labels claim, contain contaminants, or include undisclosed pharmaceutical ingredients. This is a real consumer protection issue that deserves serious regulatory attention.

Heavy metal contamination in imported herbs is another legitimate concern. The FDA’s emphasis on good manufacturing practices (GMPs) for supplement producers is directionally correct, even if implementation has been inconsistent.

Drug interaction warnings for widely consumed herbs like St. John’s Wort are based on solid pharmacological evidence. St. John’s Wort’s induction of cytochrome P450 enzymes is well documented and clinically significant for people on antiretrovirals, anticoagulants, and certain psychiatric medications.

The issue is not that the FDA has no valid points. The issue is that valid concerns about quality control and specific high-risk interactions have been used to justify a broader skepticism toward botanical medicine that is not proportionate to the actual evidence base.

What a Better Regulatory Framework Would Look Like

A genuinely useful herb regulatory framework would need to do several things differently.

Differentiate by Preparation and Dose

A freeze-dried whole root capsule, a standardized extract, an aqueous tea, and a tincture made with high-proof alcohol are four fundamentally different products even when they come from the same plant. Regulatory risk categories should reflect these differences rather than treating “herb X” as a monolithic entity.

Incorporate Traditional Use Evidence Systematically

The European Medicines Agency has developed a more nuanced model through its Committee on Herbal Medicinal Products (HMPC), which recognizes “traditional use” as a legitimate evidentiary category distinct from clinical trial evidence. This does not mean abandoning scientific rigor. It means applying appropriate methodologies to the type of knowledge being evaluated. The FDA has not adopted a comparable framework.

Invest in Quality Infrastructure Rather Than Ingredient Restriction

Rather than restricting access to specific herbs based on case reports that often involve adulterated or misused products, the FDA could invest more heavily in third-party certification infrastructure, chain-of-custody verification, and post-market surveillance. This would address the actual sources of harm more directly than upstream ingredient restrictions.

Create Proportionate Risk Tiers

Not all herbs carry the same risk profile. A regulatory system that treats ashwagandha with the same scrutiny as blue cohosh used during pregnancy is not proportionate and wastes enforcement resources that could be directed at genuinely dangerous products.

The Evidence Gap the FDA Ignores

One of the most significant omissions in the FDA’s approach is the failure to seriously engage with the substantial body of traditional and clinical evidence supporting many botanical preparations. The agency frequently frames the lack of large-scale pharmaceutical-grade randomized controlled trials (RCTs) as equivalent to a lack of evidence. These are not the same thing.

Organizations like the American Botanical Council have published extensive peer-reviewed databases and systematic reviews of herbal research. The World Health Organization has published monographs on dozens of medicinal plants synthesizing global traditional use data and available clinical evidence. Traditional Chinese medicine, Ayurveda, and European phytotherapy traditions represent accumulated observational databases spanning centuries and involving millions of people. This is not anecdote. It is a different form of evidence that deserves methodologically appropriate evaluation.

The insistence that RCTs are the only valid evidence source for safety and efficacy determinations is itself a form of epistemic bias that advantages pharmaceutical companies (which can fund large trials) over botanical traditions (which typically cannot).

Comparing Regulatory Approaches: FDA vs. Other Jurisdictions

To understand what is possible, it helps to look at how other regulatory bodies handle botanical medicines. The contrast reveals that the FDA’s current approach is not the only viable option.

The comparison is instructive. Canada’s Natural Health Products framework requires pre-market product licenses but uses a tiered evidence system that treats traditional use as a legitimate basis for safety and efficacy claims. Australia’s Therapeutic Goods Administration separates herbs into risk tiers and allows a streamlined pathway for lower-risk traditional products. The EU’s HMPC requires 30 years of documented traditional use, including 15 years within the EU, before granting traditional herbal registration. Each of these systems has genuine limitations, but all of them engage more thoughtfully with botanical evidence than the FDA’s current framework does.

The Practical Consequences for Consumers

When regulatory frameworks are poorly calibrated, real people bear the consequences. In the context of herbal medicine, there are two categories of harm worth examining.

Over-restriction harm: When herbs with strong traditional evidence and reasonable safety profiles are restricted or stigmatized based on pharmaceutical-framed risk assessments, consumers lose access to potentially beneficial options. They may turn to pharmaceutical alternatives with more significant side effect profiles, or they may purchase poorly regulated products from unverified sources, which is actually the less safe outcome.

Under-protection harm: When the FDA’s enforcement resources are spread across a vast supplement market with limited pre-market gatekeeping, genuinely dangerous products, especially adulterated supplements spiked with pharmaceutical compounds, can circulate widely before action is taken. This is where consumer harm is most concentrated and most preventable.

A smarter framework would concentrate regulatory energy on the second category while creating clearer, evidence-appropriate pathways for the first. Instead, the current approach does neither particularly well.

What Consumers Can Do Right Now

While regulatory reform moves slowly, individuals who use herbal products can take meaningful steps to protect themselves and make more informed choices.

• Choose third-party tested products. Look for herbs that have been tested by independent organizations. Programs like USP Dietary Supplement Verification or NSF International certification indicate a product has met quality and purity standards.
• Work with qualified practitioners. Herbalists, naturopathic doctors, and integrative medicine physicians can help you evaluate herb-drug interactions and appropriate preparations for your specific situation.
• Research preparation and sourcing. Where your herb comes from and how it was prepared matters enormously for both safety and efficacy. Whole-herb products, standardized extracts, and tinctures have different profiles.
• Report adverse events. The FDA’s MedWatch program allows consumers to report adverse events from supplements. This data contributes to post-market surveillance and helps identify genuine safety signals.
• Stay informed about specific herbs you use. Some herbs have well-documented contraindications with medications or specific health conditions. Knowing these before you start is more protective than any regulatory label.

FAQ: The FDA, Herbs, and What You Need to Know

Does the FDA test herbal supplements before they go on sale?

No. Under DSHEA, herbal supplements are not required to undergo pre-market FDA review or approval. The manufacturer is responsible for ensuring the product is safe and that any claims made are substantiated. The FDA can take action after a product is on the market if it receives evidence of harm or if the product is found to be adulterated or misbranded.

Are herbal supplements dangerous because the FDA does not regulate them?

The FDA does regulate supplements, just through a post-market rather than pre-market framework. The more accurate concern is not the absence of regulation but the mismatch between regulatory methodology and the nature of botanical products. Many herbs have extensive traditional use records and a reasonable safety profile in traditional preparations. The risks are highest with adulterated products, inappropriate use, or drug interactions, not with properly prepared traditional herbs used in appropriate contexts.

What is the difference between an herb and a drug according to the FDA?

According to the FDA, a drug is a substance intended to diagnose, cure, treat, or prevent a disease. If an herbal company makes a disease claim for its product, that product legally becomes a drug and must go through pharmaceutical approval. Herbs sold as dietary supplements can only make structure-function claims (such as “supports immune function”) rather than disease claims. This distinction, while legally meaningful, creates the odd situation where an herb with significant clinical evidence for a health condition cannot state that evidence on its label.

Which herbs have the most serious FDA safety concerns?

The FDA has issued safety alerts or taken enforcement actions related to several herbs and botanical ingredients over the years, including kava, comfrey (for internal use), pennyroyal, and products containing aristolochic acid. More recently, concerns have been raised about certain botanical stimulants including those containing synephrine and yohimbe at high doses. It is important to distinguish between herbs flagged due to adulteration issues versus those with genuine whole-plant toxicity evidence.

How does the EU handle herbal medicine regulation differently?

The European Union’s Traditional Herbal Medicinal Products Directive, implemented in 2004 and enforced from 2011, created a simplified registration pathway for herbal products with at least 30 years of documented traditional use. The HMPC evaluates both clinical evidence and traditional use data, producing public assessment reports that apply different evidence standards to different product categories. This means European consumers can access legally registered herbal products with clearer quality and labeling standards than is typical in the US market.

The Bottom Line

The FDA’s herbal guidelines are not malicious and they are not entirely without merit. But they are built on a framework that was never designed for botanical medicine, and the result is a regulatory posture that is simultaneously too restrictive in some areas and not protective enough in others. The solution is not deregulation. It is smarter, more proportionate, and more epistemically honest regulation that takes traditional use evidence seriously, invests in quality infrastructure, and concentrates enforcement where harm is actually concentrated. Until that happens, consumers bear the burden of navigating an imperfect system as best they can, with good information as their most reliable tool.